Title : Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.

Pub. Date : 2005 Jan

PMID : 15528979






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Lapatinib epidermal growth factor receptor Homo sapiens
2 GW572016 is a dual EGFR-ErbB2 inhibitor that has promise as an anticancer agent. Lapatinib epidermal growth factor receptor Homo sapiens